In this special episode of DTx Podcast, Eugene is joined by Brent Vaughan, CEO of Cognito, as well as industry leaders from previous episodes, to weigh in on the recent Pear Therapeutics news and the future of prescription digital therapeutics.
In this episode, we cover:
The impact on the PDT market
Future efforts to move DME to PDT
The impact on the entrepreneurs currently developing PDT’s
Predictions on the future of Pear Therapeutics
Reflections on the history and future of DTx from Chris Bergstrom (Amalgam RX), David Klein (Click Therapeutics), Andy Molnar (DTA), Sammeli Liikkanen (Orion), Francesca Wuttke (nen), Andrzej Jonczyk (Prosoma), Steve Driver (Advocate Health) and Grady Hannah (NightWare)
Join the HealthXL platform for free today and be the first to read their analysis of Pear’s predicament and what it means for the DTx industry: https://portal-beta.healthxl.com/?s=2fb5
Guest Links and Resources:
Connect with Brent Vaughan on LinkedIn
Connect with Chris Bergstrom on LinkedIn
Connect with David Klein on LinkedIn
Connect with Andy Molnar on LinkedIn
Connect with Sammeli Liikkanen on LinkedIn
Connect with Francesca Wuttke on LinkedIn
Connect with Andrzej Jonczyk on LinkedIn
Connect with Steve Driver on LinkedIn
Connect with Grady Hannah on LinkedIn
Host Links:
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram
Special Episode: Industry Leaders Weigh in on the Recent Pear Therapeutics News and the Future of Prescription Digital Therapeutics